What is the role of intraperitoneal (IP) chemotherapy in the treatment of stage III ovarian cancer?

Updated: Jan 14, 2019
  • Author: Shannon M Grabosch, MD; Chief Editor: from Memorial Sloan-Kettering - Yukio Sonoda, MD  more...
  • Print


Intraperitoneal (IP) chemotherapy remains the preferred treatment for optimally debulked (< 1 cm) stage III ovarian cancer after front-line surgery. A Gynecological Oncology Group trial (GOG 172) that compared IV cisplatin and IV paclitaxel with IP cisplatin and IV/IP paclitaxel determined that IP therapy improved survival and yielded a 25% reduction in the risk of death. However, the trial also showed increased toxicity with IP chemotherapy versus IV chemotherapy. [10]

The recently reported preliminary results of GOG 252 are somewhat contradictory, with no significant difference in progression-free survival (PFS) between patients receiving IV carboplatin/weekly IV paclitaxel; IP carboplatin/weekly IV paclitaxel; or sequential IV paclitaxel, IP cisplatin (dosed at 75 mg/m2), and IP paclitaxel. However, the 28% crossover rate from IP treatment to the IV-only group may have watered down a significant difference in PFS. [11] Furthermore, the addition of bevacizumab to all arms in the study may have contributed to the unexpected results.  Overall survival data have not yet matured.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!